Avelumab and Merkel Cell Carcinoma: Examining the Scientific Evidence for Causation

From General Health Information to Occupational Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of disease prevention and treatment. Within this heritage, discussions of therapeutic interventions—such as immunotherapies—have typically focused on their benefits in managing illness. However, as scientific inquiry deepens, the same informational frameworks must now accommodate emerging questions about unintended consequences of pharmaceutical exposure. This transition is particularly relevant when considering the drug avelumab, a monoclonal antibody approved for certain cancers, including Merkel cell carcinoma. While avelumab is prescribed as a treatment, occupational exposure to this agent—especially in manufacturing, clinical administration, or waste handling settings—raises distinct concerns. Workers in these environments may encounter the drug through inhalation, dermal contact, or accidental injection, prompting a shift from patient-centered health narratives to occupational risk assessment. The bridge from general health context to avelumab exposure thus requires acknowledging that substances designed for therapeutic use can, under occupational conditions, become hazards. This pivot does not assert causation but rather establishes a logical continuum: from broad health education to focused scrutiny of workplace safety, where the same scientific rigor applied to patient outcomes must now be directed toward understanding exposure scenarios and their potential implications for worker health.

Avelumab as a Therapeutic Agent for Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and it is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence rate is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Scientific Evidence: Avelumab Treats, Does Not Cause, Merkel Cell Carcinoma

The scientific evidence connecting avelumab to Merkel cell carcinoma is not one of causation but rather of therapeutic indication. Avelumab is used to treat MCC, not to cause it. The evidence demonstrates that avelumab is an effective treatment for metastatic MCC, with clinical trials showing objective responses in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, for patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In such cases, combined therapy with ipilimumab plus nivolumab has been investigated as a subsequent treatment option, with some patients responding according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Mechanistic pathways linking avelumab to MCC are centered on its role as an immune checkpoint inhibitor. Avelumab blocks PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells, including MCC cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). This mechanism is the basis for its therapeutic effect. However, checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case of hypercalcaemia due to reactivation of sarcoidosis during treatment with avelumab for metastatic MCC has been reported, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while avelumab can cause immune-related adverse effects, these are distinct from causing the primary disease.

Risk Context and Clinical Interpretation

In terms of risk anchors and safety-communication context, the evidence does not support a causal link between avelumab and the development of MCC. Instead, avelumab is a treatment for MCC. The timeline between exposure and documented health outcomes is consistent with its use as a therapeutic agent: patients with existing MCC receive avelumab, and outcomes such as tumor response or progression are monitored over time (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who are avelumab-refractory, subsequent treatments may be considered, but the evidence does not indicate that avelumab itself causes MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). Causation-focused clinical interpretation for affected patients should emphasize that avelumab is a standard therapy for metastatic MCC, not a cause of the disease. Patients who experience progression on avelumab may have limited options, but combined immune checkpoint inhibition with ipilimumab plus nivolumab has shown activity in avelumab-refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The evidence underscores the importance of monitoring for immune-related adverse events during avelumab therapy, but these are manageable and do not indicate that the drug causes MCC. In summary, the scientific evidence consistently positions avelumab as a treatment for Merkel cell carcinoma, not as a causative agent. The pharmacological mechanism, clinical trial data, and safety profile all support its role in managing this aggressive cancer. Any suggestion of causation would be inconsistent with the evidence, which instead highlights avelumab's therapeutic benefit and the challenges of managing refractory disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab does not cause Merkel cell carcinoma. It is a treatment for metastatic Merkel cell carcinoma. Clinical trials and scientific evidence consistently show that avelumab is used to treat MCC, not to cause it (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What is the mechanism of action of avelumab in Merkel cell carcinoma?

Avelumab is an immune checkpoint inhibitor that blocks PD-L1, enhancing the immune system's ability to recognize and attack cancer cells, including Merkel cell carcinoma cells (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the treatment options for patients with avelumab-refractory Merkel cell carcinoma?

For patients who progress on avelumab, combined therapy with ipilimumab plus nivolumab has shown activity in some cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.